ACTC
Demasiado bonito para ser cierto. ¿Quién es este pavo?
Ray Gordon Stands By $8.00 Price Target On ACTC
A lot of chatter has circulated on various websites and boards regarding Advanced Cell Technology Corporation (ACTC), the fledgling regenerative-medicine stem-cell company which some believe will dominate this emerging field. Until science or bankruptcy proves otherwise, I see no reason to abandon my $8.00 price target for this stock, based on parity (at the time of the prediction) with Regeneron (REGN), now a $28.5b company on the basis of its recent closing price, mostly on the strength of Eylea, its "landmark" drug that slows the progression of wet Advanced Macular Degeneration (AMD). By contrast, ACTC's RPE cell treatment for dry AMD (and Stargaart's) has shown safety, and strong efficacy in a trial designed only to prove safety. One patient has improved his sight from 20/400 to 20/40 in three weeks, making reality out of the promise that swept the medical-research community with the genome project in 1993, during which time I was working fo a top medical research center that had recruited a top "gene therapy" doctor of the day. I made a mental note to track the progress of this science, while avoiding its stock offerings, due to the potential for insider maipulation. With the science now at hand, this concern has lessened.
ACTC's share price has taken a hit lately, to $0.0585, after its 10-K filing shows very little liquidity, a number of "hit pieces" in other media have made unfounded attacks on both ACTC's patent rights,and even its underlying science. Meanwhile, Dr. Lanza has been quoted twice in peer-reviewed medical journals, including a study that showed embryonic cells were 30,000x more potent than the adult-cell alternatives our government chose to fund for political rather than scientific reasons. Dr. Lanza was the only man who stayed the course, resulting in a patent sweep for ACTC which will pay off huge soon. The company should have little difficulty raising cash as they need to, and once the results from their RPE study are published in a major journal, and the public realizes just how deep and game-changing their pipeline really is, the stock shold"go viral" and hit the stratosphere. Any buyout attempt is likely to result in a bidding war, so that is not a major concern.
Beware of pretenders in this sector who are piggybacking the regenerative-medicine concept while exploitking public ignorance about their true market position, or their underlying science. ACTC is the real deal, and while the non-embryonic companies mayu have their place, that place should be that of a distant also-ran to what very well could become the world's first trillion-dollar clompany. At $0.0585 a share, a mere $5,850.00 would buy 1000,000 shares, enough to becmoe a millionaire if ACTC does nothing more than match Regeneron's current market cap. Issues such as a cash crunch, or dilution, will seem minor in hindsight.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
